Quick Answer
Theravance Biopharma, Inc. reported Diluted EPS of $2.06 per share for fiscal year 2025.
Theravance Biopharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $2.06 | +279.1% |
| 2024 | -$1.15 | -15.0% |
| 2023 | -$1.00 | -108.4% |
| 2022 | $11.85 | +512.9% |
| 2021 | -$2.87 | +35.7% |
| 2020 | -$4.46 | -4.9% |
| 2019 | -$4.25 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.07 | +126.9% | -93.5% |
| June 30, 2025 | $1.08 | +417.6% | +500.0% |
| March 31, 2025 | -$0.27 | -12.5% | -3.8% |
| September 30, 2024 | -$0.26 | -52.9% | +23.5% |
| June 30, 2024 | -$0.34 | -21.4% | -41.7% |
| March 31, 2024 | -$0.24 | +31.4% | -41.2% |
| September 30, 2023 | -$0.17 | -101.4% | +39.3% |
| June 30, 2023 | -$0.28 | -154.5% | +20.0% |
- Theravance Biopharma, Inc. showed an increase of +279.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Theravance Biopharma, Inc.’s diluted eps has grown by 148.5% (from $4.25 per share (loss) to $2.06 per share).
- The most recent figure is from Theravance Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: